UBS Adjusts Numbers on Amgen (AMGN); Tough ODAC for Xgeva
AMGN Hot Sheet
Rating Summary:6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
UBS maintains a 'Neutral' on Amgen (NASDAQ: AMGN) price target cut $1 to $69.
UBS analyst says, "Not surprisingly, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 12-1 that a favorable benefit-risk profile was not established for Xgeva in the prevention of bone metastases in high-risk prostate cancer patients. Most of the panel’s issues boiled down to whether there was any incremental benefit of treating sooner (in prevention) than later (in treatment of bone metastases, or SRE setting)...The silver lining here may be that limiting Xgeva usage to the SRE setting may ultimately result in a better perceived safety profile for Xgeva."
UBS lowers FY12 EPS estimate from $6.14 to $6.10 and FY13 from $6.75 to $6.69.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $68.06 yesterday, with a 52 week range of $47.66-$70.00.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
UBS analyst says, "Not surprisingly, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 12-1 that a favorable benefit-risk profile was not established for Xgeva in the prevention of bone metastases in high-risk prostate cancer patients. Most of the panel’s issues boiled down to whether there was any incremental benefit of treating sooner (in prevention) than later (in treatment of bone metastases, or SRE setting)...The silver lining here may be that limiting Xgeva usage to the SRE setting may ultimately result in a better perceived safety profile for Xgeva."
UBS lowers FY12 EPS estimate from $6.14 to $6.10 and FY13 from $6.75 to $6.69.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $68.06 yesterday, with a 52 week range of $47.66-$70.00.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Barclays Comments on Wesco Aircraft Holdings (WAIR) Acquisition of Interfast; Deal Accretive to 2013
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, FDARelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
